DoW Melanoma Research Program Idea Award | HT942526MRPIA

FY26 DoD Melanoma Research Program (MRP) Idea Award (HT942526MRPIA) - FAQs

What is the FY26 DoD Melanoma Research Program (MRP) Idea Award?

The FY26 Department of Defense (DoD) Melanoma Research Program (MRP) Idea Award is a discretionary grant competition administered through the Defense Health Agency Contracting Activity (DHACA). It supports bold, early-stage melanoma research concepts that are intentionally high-risk but could produce high impact if successful.

What is the funding opportunity number for this grant?

The Funding Opportunity Number is HT942526MRPIA.

What is the main purpose of the Idea Award?

The award is designed to act as a catalyst for new melanoma research directions by helping investigators reach a proof of principle by the end of the funding period and generate enough early evidence to pursue follow-on funding from other sources.

What kinds of research does this opportunity support?

It supports exploratory, innovative melanoma research that could open new directions in melanoma prevention, detection, biology, or treatment. The emphasis is on originality and potential impact rather than incremental advances on well-established work.

How important are novelty and innovation for this award?

Novelty and innovation are central expectations. Reviewers will be looking for ideas that challenge current assumptions, introduce new approaches, or test unconventional hypotheses that could meaningfully move the field forward if they work.

Is this opportunity intended for high-risk projects?

Yes. The Idea Award is specifically positioned for intentionally high-risk, early-stage concepts where outcomes may be uncertain, but the potential payoff could be significant.

Are incremental or confirmatory studies a good fit?

Based on the description provided, the program is oriented toward exploratory projects and originality, not incremental advances on well-established work. Proposals that mainly extend existing lines of research in a predictable way may not align with the stated intent.

What is meant by "proof of principle" in this context?

In this listing, proof of principle refers to producing interpretable early findings that demonstrate feasibility, validate a promising concept, and reduce uncertainty enough to justify larger next-step investment after the award ends.

What is the expected outcome by the end of the funding period?

The program expects investigators to have tested the concept in a way that yields early, interpretable results and a clear feasibility signal, positioning the project to compete for follow-on support from other funding sources.

Is preliminary data required?

No. Preliminary data are discouraged, indicating applicants are not expected to already have extensive supporting results and that the opportunity is deliberately making room for very early-stage ideas.

If preliminary data are discouraged, what should applications emphasize instead?

Based on the description, applications should emphasize the strength and originality of the idea, the soundness and credibility of the plan to test it, why it matters for melanoma, what key risk or knowledge gap it addresses, and what early milestones will demonstrate feasibility or proof of principle.

Is there a required pre-application step?

Yes. The process is gated: a pre-application is required first, and only applicants who receive an invitation after that step may submit a full application.

Can an applicant submit a full application without being invited?

No. Only those invited after the required pre-application step are allowed to submit a full application.

Why does the program use a gated application process?

The listing indicates the pre-application functions as a screening mechanism so the program can concentrate full proposal review resources on the most compelling and program-relevant ideas.

Who is eligible to apply?

Eligibility is listed as unrestricted, suggesting a broad range of applicant organizations or investigators may be able to apply, subject to standard federal and program requirements.

How many awards are anticipated?

The posting indicates an anticipated 10 awards.

What is the closing date for this opportunity?

The original closing date is October 14, 2026.

When was the opportunity created?

The opportunity was created on May 21, 2026.

What funding instrument is used?

This opportunity uses the grant funding instrument.

How is the opportunity categorized administratively?

It is categorized under Science and Technology and other Research and Development.

What is the CFDA number associated with this opportunity?

The CFDA number listed is 12.420.

Is an award ceiling or maximum budget specified in the listing?

No. An award ceiling is not specified in the provided listing. Applicants would need to consult the full solicitation or program announcement for budget limits, period of performance, and any cost-related constraints.

Does the listing include details like period of performance and cost constraints?

No. The summary provided notes that these details are not specified in the listing and should be confirmed in the full solicitation or program announcement.

What types of applicants are likely to be most competitive?

Based on the description, the strongest proposals will typically present a genuinely novel melanoma-focused concept with a credible, well-reasoned plan to test it quickly and decisively, even if unconventional, and will clearly define early milestones that demonstrate feasibility and support future follow-on funding.

What should a strong proposal argue or demonstrate?

A strong proposal should make a clear case for why the idea is new, why it matters for melanoma, what key risk or knowledge gap it addresses, and what specific early milestones will demonstrate feasibility or proof of principle and set up next-step investment.

What melanoma areas are explicitly mentioned as within scope?

The listing explicitly mentions melanoma prevention, detection, biology, and treatment as areas where new directions could be opened through this award.